Avalon GloboCare Appoints Dr. Yen-Michael Sheng Hsu, Founding Director of cGMP Cellular Therapy Facility at Weill Cornell Med...
June 26 2019 - 8:30AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer
of cell-based technologies and therapeutics, announced today that
the Company has appointed Yen-Michael S. Hsu, M.D., Ph.D. to its
Scientific and Clinical Advisory Board.
Dr. Yen-Michael Sheng Hsu is currently the Director of
Laboratory for Advanced Cellular Therapy at Weill Cornell Medicine.
At Cornell, Dr. Hsu, as the founding director, has led the
establishment of a cGMP cellular therapy facility, the
first-of-its-kind in the history of Weill Cornell Medicine. In
addition, Dr. Hsu is head of the Laboratory for Advanced Cellular
Engineering at New York-Presbyterian Hospital. Dr. Hsu has received
many scholar recognitions from various professional societies and
has significantly contributed to medical student and clinician
trainee educations. He specializes in regenerative medicine, cell
therapy/exosome standardization, and immunotherapy research.
Professionally, Dr. Hsu takes on many major leadership positions in
cell therapy related societies, such as Foundation for the
Accreditation of Cellular Therapy (FACT) and AABB. He is currently
a key inspector (both FACT and AABB) for cell therapy laboratory
accreditation with a particular focus in the Asia Pacific region.
Dr. Yen-Michael Sheng Hsu has over 30 peer-reviewed publications in
top-tier journals, including Nature, Nature Medicine, and Nature
Immunology. Dr. Hsu graduated from UC Berkeley with an honor
distinction. Subsequently, he received both an MD and a PhD from
the University of Texas Medical School at Houston and MD Anderson
Cancer Center. Dr. Hsu also completed his pathology residency
training at the Washington University School of Medicine and
fellowship in transfusion medicine and cell therapy at the UCSF
Medical Center.
“We are pleased to welcome Dr. Hsu to our Scientific and
Clinical Advisory Board. He has been an invaluable asset in
our exosome-based clinical programs for liquid biopsy and
regenerative therapeutics. He also brings a wealth of
knowledge, experience and leadership in cellular therapy, and has
an impressive track record in both translational and clinical
research fields,” stated David Jin, M.D., Ph.D., President and
Chief Executive Officer of Avalon GloboCare. “Dr. Hsu’s
expertise in tissue-specific exosome and cellular immunotherapy
will be of significant value in supporting Avalon’s pipeline as we
advance to our next phase of clinical development of
next-generation CAR-T therapy as well as commercialization of
clinical-grade exosome products,” added Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech
bio-developer dedicated to advancing and empowering innovative,
transformative exosome technologies and cellular therapeutics.
Avalon also provides strategic advisory and outsourcing services to
facilitate and enhance its clients' growth, development, as well as
competitiveness in both the domestic and global healthcare markets.
Through its subsidiaries, namely GenExosome Technologies Inc. and
Avactis Biosciences Inc., Avalon is establishing a leading role in
the fields of exosome-based diagnostics (''liquid biopsy''),
cellular immunotherapy (including CAR-T/CAR-NK), and regenerative
medicine.
Forward-Looking Statements Certain statements
contained in this press release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations: Crescendo Communications,
LLC Tel: (212) 671-1020 Ext. 304 avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024